Measuring heart-related biomarkers in children with dengue shock
NT-proBNP and Troponin I in Children With Dengue Hemorrhagic Shock: a Longitudinal Study
University of Medicine and Pharmacy at Ho Chi Minh City · NCT04837430
This study is trying to see if certain heart-related markers in the blood can help doctors better manage children with severe dengue shock syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 1 Month to 18 Years |
| Sex | All |
| Sponsor | University of Medicine and Pharmacy at Ho Chi Minh City (other) |
| Locations | 1 site (Ho Chi Minh City) |
| Trial ID | NCT04837430 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the concentrations of NT-proBNP and Troponin I in children suffering from Dengue Shock Syndrome. It will explore the correlation between these biomarkers and clinical factors such as total fluid admission, respiratory support, and the use of inotropes and vasopressors. The study focuses on improving the understanding of fluid overload in these patients, which is a significant challenge in their management. By identifying potential biomarkers, the study seeks to enhance treatment strategies for severe cases of dengue in children.
Who should consider this trial
Good fit: Ideal candidates for this study are children diagnosed with Dengue Shock Syndrome who are admitted to the ICU.
Not a fit: Patients with pre-existing cardiovascular diseases or those on specific medications like insulin or steroids may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better management strategies for children with Dengue Shock Syndrome, potentially reducing morbidity and mortality.
How similar studies have performed: While the use of NT-proBNP and Troponin I as biomarkers in other conditions has shown promise, this specific application in Dengue Shock Syndrome is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Dengue shock children who admitted to ICU Exclusion Criteria: * Excluding the cases of children with cardiovascular disease, hyperthyroidism, taking drugs such as insulin, steroid, estrogen, growth hormone, thyroid hormone
Where this trial is running
Ho Chi Minh City
- University of medicine and pharmacy at Ho Chi Minh city — Ho Chi Minh City, Vietnam (RECRUITING)
Study contacts
- Principal investigator: Truyen P. Le, MD — University of Medicine and Pharmacy at Ho Chi Minh City
- Study coordinator: Le P. Truyen, MD
- Email: dr.letruyen@ump.edu.vn
- Phone: +84 903640025
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Dengue Shock Syndrome, Children, Only, NT-proBNP, Troponin I, Dengue children, Cardiac enzyme